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PHeart Rhythm Disorders
redictive Value of Ventricular
rrhythmia Inducibility for Subsequent
entricular Tachycardia or Ventricular
ibrillation in Multicenter Automatic
efibrillator Implantation Trial (MADIT) II Patients
ames P. Daubert, MD,* Wojciech Zareba, MD, PHD,* W. Jackson Hall, PHD,† Claudio Schuger, MD,‡
ndrew Corsello, MD,§ Angel R. Leon, MD, Mark L. Andrews, MS,* Scott McNitt, MS,*
avid T. Huang, MD,* Arthur J. Moss, MD,* for the MADIT II Study Investigators
ochester, New York; Detroit, Michigan; Portland, Maine; and Atlanta, Georgia
OBJECTIVES We correlated electrophysiologic inducibility with spontaneous ventricular tachycardia (VT)
or ventricular fibrillation (VF) in the Multicenter Automatic Defibrillator Implantation Trial
(MADIT) II.
BACKGROUND In the MADIT II study, 593 (82%) of 720 implantable cardioverter-defibrillator (ICD)
randomized patients underwent electrophysiologic testing. Patients received an ICD whether
they were inducible or not.
METHODS A “standard” inducibility definition included sustained monomorphic or polymorphic VT
induced with three or fewer extrastimuli or VF induced with two or fewer extrastimuli. We
compared a narrow inducibility definition (only monomorphic VT) and a broad definition
(standard definition plus VF with three extrastimuli). We used ICD-stored electrograms to
categorize spontaneous VT or VF.
RESULTS Inducible patients (standard definition) had a greater likelihood of experiencing ICD therapy
for VT than noninducible patients (p  0.023). Unexpectedly, ICD therapy for spontaneous
VF was less common (p  0.021) in inducible patients than in noninducible patients. The
two-year Kaplan-Meier event rate for VT or VF was 29.4% for inducible patients and 25.5%
for noninducible patients. Standard inducibility did not predict the combined end point of
VT or VF (p 0.280, by log-rank analysis). The narrow inducibility definition outperformed
the standard definition, whereas the broad definition appeared inferior to the standard
definition.
CONCLUSIONS In the MADIT II study patients, inducibility was associated with an increased likelihood of
VT. Noninducible MADIT II study subjects using this electrophysiologic protocol had a
considerable VT event rate and a higher VF event rate than inducible patients. Induction of
polymorphic VT or VF, even with double extrastimuli, appears less relevant than induction
of monomorphic VT. (J Am Coll Cardiol 2006;47:98–107) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.049College of Cardiology Foundation
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rial (MADIT) II reduced the risk of all-cause mortality
See page 108
y 31% in patients after myocardial infarction (MI) with an
jection fraction of 0.30 or less (1). This trial was the first to
nroll patients without a previous incident of sustained
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f Rochester School of Medicine and Dentistry.f
Manuscript received January 8, 2005; revised manuscript received April 13, 2005,
ccepted August 1, 2005.entricular arrhythmia or inducibility as a requirement.
nlike the MADIT II study, previous prophylactic ICD
rials (2,3) excluded noninducible patients on the basis of
he belief that electrophysiologic (EP) inducibility identified
group at increased risk for sudden death. The Multicenter
nSustained Tachycardia Trial (MUSTT) substudy results
4) did demonstrate a significantly increased risk of mortal-
ty in EP-inducible patients compared with noninducible
atients. However, the two-year total mortality of inducible
atients (28%) was only 1.33-fold greater than for nonin-
ucible patients (21%), implying that inducibility had mod-
st clinical relevance in these post-MI patients (4). Further-
ore, EP testing was even less predictive in patients with an
jection fraction of 0.30 or less (5). Thus, it is unclear how
ell EP inducibility functions as a screening test to select
ostinfarction patients fitting the MADIT II study criteria
or ICD implantation.
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January 3, 2006:98–107 EPS in the MADIT II StudyThe evaluation of inducibility as a predictor of arrhythmic
vents was a prespecified secondary objective of the
ADIT II study. Thus, the MADIT II study protocol
trongly encouraged patients randomly assigned to the ICD
rm of the MADIT II study to undergo EP inducibility
esting but for ICD implantation to be performed regardless
f inducibility status. To maximize statistical power to
ddress the role of EP testing, ICD to conventional ran-
omization was 3:2 (1,6). Arrhythmia end points, i.e.,
entricular tachycardia (VT) or ventricular fibrillation (VF),
ere determined using ICD interrogation data. We then
valuated the association between EP inducibility and sub-
equent ventricular arrhythmia and also with mortality. We
valuated whether classification of patients by inducibility
tatus and baseline QRS duration (7–10) would predict
rrhythmic events as well. Therefore, this study addressed
hether ICD implantation in post-MI patients with an
jection fraction of 0.30 or less should be limited to those
ound to be inducible or whether otherwise-similar but
oninducible patients also are at significant risk of life-
hreatening ventricular arrhythmia.
ETHODS
he MADIT II study (1) prospectively enrolled 1,232
atients with a previous MI and an ejection fraction of 0.30
r less. Of the 742 patients randomized to the ICD arm of
he trial, 720 subjects actually received an implanted defi-
rillator. Electrophysiologic testing for ventricular tachycar-
ia inducibility was recommended before the implantation
f the ICD but was not a mandatory protocol requirement.
f the 720 ICD implant patients, 593 underwent EP
esting, and this latter group is the cohort used in the
resent study.
P testing and inducibility definitions. The EP testing
rotocol used 400-ms and 600-ms drive trains followed by
ne to three ventricular extrastimuli that were 2 ms in
uration at twice the diastolic threshold (1,6,11). Extra-
timuli were decremented down to a coupling interval no
horter than 180 ms. Stimulation was performed at one
ight ventricular (RV) site and then repeated at a second RV
ite. Rapid burst pacing was not used for induction. A
atheter-based EP testing study was recommended, but
Abbreviations and Acronyms
ATP  anti-tachycardia pacing
EP  electrophysiologic
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MI  myocardial infarction
RV  right ventricular
VF  ventricular fibrillation
VT  ventricular tachycardianducibility was determined through the ICD in 13% of the iroup. The EP study end point included the induction of a
ustained monomorphic VT, polymorphic VT, or VF epi-
ode or completion of the protocol. A sustained ventricular
rrhythmia was defined as one lasting 30 s or requiring
ermination sooner because of hemodynamic compromise.
Monomorphic VT was defined as a VT with a uniform
eat-to-beat surface QRS morphology. Polymorphic VT
ad a variable surface QRS morphology, and VF was
efined as a rapid, disorganized rhythm without consistently
dentifiable complexes. A prespecified definition, i.e., stan-
ard inducibility, included sustained monomorphic VT
nduced with three or fewer extrastimuli, polymorphic VT
nduced with three or fewer extrastimuli, and VF induced
ith two or fewer ventricular extrastimuli. We also evaluated
wo alternative inducibility definitions, narrow inducibility
also prespecified), which included only sustained monomor-
hic VT, and a broad definition, which included the
tandard inducibility criteria plus VF induced with three
xtrastimuli.
nalysis of ICD therapy. Patients in the MADIT II ICD
tudy arm underwent quarterly ICD interrogation as well as
nterim visits if their symptoms dictated (1). Centers com-
leted ICD follow-up data forms describing each ICD
herapy (anti-tachycardia pacing [ATP] or shock) and
ownloaded ICD interrogation to discs. All ICD interro-
ation data were reviewed by an ICD end point committee
omposed of three of the authors (J.P.D., W.Z., and A.C.),
ho adjudicated each ICD event. The ICD end point
ommittee was blinded to the results of the EP study results.
e classified ICD therapy occurring for VT or VF as
ppropriate. Inappropriate therapy, due to atrial fibrillation,
upraventricular tachycardia, or abnormal sensing, amount-
ng to 35.4% of ICD events or therapy events that could not
e classified (2.3% of total ICD events), was not included in
his analysis.
The ICD end point committee reviewed all available
nformation, including the ICD episode summary, stored
ntracardiac electrograms, and the enrollment center’s
hythm classification. If applicable, the event was considered
n the context of other episodes for the same patient. The
riggering arrhythmia was characterized as VT if the rate
as between 140 and 250 beats/min and the complexes were
niform and regular. The arrhythmia was characterized as
F if the rate was 200 beats/min, if the rhythm was
rregular, and if the electrogram complexes were indistinct.
olymorphic VT was included with VT when 200 beats/
in and with VF if the rate was 200 beats/min. Ventric-
lar tachycardia was differentiated from supraventricular
achycardia using standard criteria, including a change in
lectrogram morphology, sudden onset, and the atrial-
entricular relationship if atrial electrograms were available.
tatistical analysis. The primary end point for this study
as the incidence of spontaneous VT or fibrillation requir-
ng treatment by the ICD in relationship to EP inducibility
t electrophysiologic testing. Clinical characteristics of the
nducible and noninducible groups were compared using the
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EPS in the MADIT II Study January 3, 2006:98–107test or F test, chi-square method, or Wilcoxon/Kruskal-
allis rank sum test where appropriate. Kaplan-Meier
urvival curves with log-rank test evaluated univariate asso-
iations between EP inducibility and outcome events (12).
o test the combined predictive value of inducibility plus
RS width, QRS duration was dichotomized into 0.12 s
n  286) and QRS 0.12 s (n  307). We used Cox
roportional hazards modeling to analyze the association
etween inducibility and outcome after adjustment for
linical covariates (13). Significance was evaluated by p 
.05.
ESULTS
linical characteristics and inducibility findings. Pa-
ients in the MADIT II ICD study arm who underwent
lectrophysiologic testing (n  593) were very similar in
easured clinical characteristics to those patients who did
ot undergo electrophysiologic testing (n 126). Statistical
ifferences present included more patients with a history of
ew York Heart Association functional class II to IV heart
ailure in the patients not undergoing an EP study (77% vs.
4%, p  0.006) and more patients being on angiotensin
eceptor blockers (19% vs. 12%, p 0.03). We compared the
vent rates in patients undergoing an EP study versus those
ho did not undergo an EP study. Twenty-four percent of
atients undergoing an EP study versus 22% of those not
ndergoing an EP study reached the end point of VT or VF
n follow-up. In addition, the EP study and no EP study
able 1. Clinical Characteristics of Patients by Inducibility Type
Clinical Characteristics
Monomorphic VT
(n  169)
ale 151 (89%)
ge (yrs) 62  12
onths post-MI* 90 (33, 164)
hites 154 (91%)
iabetes 53 (31%)
ypertension 81 (48%)
moking 139 (82%)
YHA functional class I or II† 122 (73%)
revious CABG 97 (57%)
revious PTCA† 74 (44%)
eart rate (beats/min)* 70  13
ystolic BP (mm Hg) 121  17
iastolic BP (mm Hg) 70  10
UN (mg/dl) 22  10
RS (ms) 121  29
jection fraction 100 22  5
nrollment medications
Beta-blockers 114 (67%)
Digitalis 103 (61%)
ACE inhibitors† 145 (86%)
Lipid agents 114 (67%)
alues shown are numbers of patients with percent of group in parentheses, or mean
edian values, and in parentheses, the interquartile range, are shown. NYHA function
p  0.001 and †0.001  p  0.05; p values for any differences among the four gro
ACE angiotensin-converting enzyme; BP  blood pressure; BUN  blood urea n
ssociation; PTCA  percutaneous transluminal coronary angioplasty; VF  ventricular firoups did not differ in the subsequent occurrence of
ospitalization for CHF, recurrent MI, cardiac death,
udden death, or total mortality.
Sustained monomorphic VT was induced in 169 (29%)
atients, sustained polymorphic VT in 26 (4%) patients, VF
ith single or double extrastimuli in 16 (3%) patients, and
F with triple extrastimuli in 32 (5%) of patients. Thus,
9% of patients met narrow inducibility, 36% of patients
et the standard inducibility definition, and 41% of patients
ad broadly defined inducibility.
The clinical characteristics for the noninducible and
nducible patients by the type of arrhythmia induced are
hown in Table 1. Sesselberg et al. (14) have previously
hown that inducible patients, defined by the standard
efinition (Table 1, columns two and three), bore similar
linical characteristics to the noninducible patients (Table 1,
olumns four and five). They found that the inducible group
ad a slightly slower heart rate, a tendency towards lower New
orkHeart Association functional class status, a slightly higher
ercent of patients on angiotensin-converting enzyme inhibi-
or therapy and a slightly longer time from most recent MI to
ate of EP study as compared with the noninducible group
14). Using the more detailed breakdown of inducibility,
.e., Table 1, differences in clinical characteristics between
he four subgroups regarding inducibility were similar to the
revious analysis (14) and included interval after infarction,
eart rate at enrollment, frequency of previous non-coronary
rtery bypass grafting revascularization, and treatment with
ngiotensin-converting enzyme inhibitors (Table 1).
olymorphic VT
VF With S2–3
(n  42)
VF With S4
(n  32)
Neither VT Nor
VF Induced
(n  350)
33 (79%) 25 (78%) 289 (83%)
62  11 65  10 64  10
34 (16, 75) 54 (29, 128) 61 (17, 117)
33 (79%) 29 (91%) 303 (87%)
13 (31%) 9 (28%) 127 (36%)
24 (57%) 19 (59%) 187 (54%)
34 (81%) 24 (75%) 274 (79%)
37 (88%) 20 (63%) 232 (67%)
22 (52%) 18 (56%) 209 (60%)
24 (57%) 21 (68%) 142 (41%)
69  10 70  12 74  13
122  18 124  14 123  19
71  11 71  10 72  11
21  9 23  16 24  13
123  35 117  29 120  31
23  5 24  5 23  6
30 (71%) 26 (81%) 215 (61%)
20 (48%) 16 (50%) 213 (61%)
33 (79%) 22 (69%) 268 (77%)
31 (74%) 26 (81%) 229 (65%)
ndard deviation, except for months post-myocardial infarction (MI) where the 50%
s represents the most severe NYHA class within the three months before enrollment.P
or
s  sta
al clas
ups.itrogen; CABG  coronary artery bypass grafting; NYHA  New York Heart
brillation; VT  ventricular tachycardia.
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January 3, 2006:98–107 EPS in the MADIT II StudyCD therapy events related to standard inducibility
efinition. At least one appropriate ICD therapy was
elivered in 141 (24%) of the 593 ICD arm patients who
nderwent EP testing. A total of 963 appropriate ICD
vents occurred in these 593 patients. Figure 1A shows the
umulative probability of first appropriate ICD therapy (for
ither VT or VF) related to inducibility per the standard
efinition. Using log-rank analysis of the cumulative prob-
igure 1. Cumulative probability of first appropriate therapy for (A)
entricular tachycardia (VT) or ventricular fibrillation (VF); (B) VT only;
nd (C) VF only in patients with and without inducible arrhythmias
ccording to standard definition of inducibility. Determination of p values
as from the log rank test.bility of a VT or VF event, inducible patients were not vore likely to receive appropriate ICD therapy than non-
nducible patients (p  0.28). The two-year point estimate
f the incidence of at least one therapy for either VT or VF,
9.4% and 25.5% respectively, also was not significantly
ifferent between inducible and noninducible patients by
he z-test (p  0.407).
Considering ICD treatment for VT only (versus either
T or VF), inducible patients defined by the standard
efinition were significantly more likely by log-rank analysis
o experience a first ICD therapy for VT (p  0.023). For
xample, at two years, 29.0% of the inducible patients and
9.3% of the noninducible patients received at least one
herapy for VT using Kaplan-Meier analysis (Fig. 1B).
Unexpectedly, the noninducible group had a significantly
igher cumulative likelihood of ICD treatment for a VF
pisode than the inducible group by log-rank analysis (p 
.021) (Fig. 1C). The two-year Kaplan-Meier event rate for
first therapy for VF was 3.2% for the inducible patients
nd 8.6% for the noninducible patients.
The aforementioned univariate associations were tested
n the multivariate Cox model adjusting for relevant clinical
ovariates (Table 2). According to this proportional hazards
nalysis, EP inducibility by the standard definition was not
ssociated with the combined end point of VT or VF
hazard ratio [HR] 1.34; p  0.094). However, ICD
herapy for VT only was predicted by EP inducibility with
HR of 1.66 (p  0.007), whereas inducibility was
ssociated with a trend toward a decreased risk of therapy
able 2. Hazard Ratio for Outcomes by Definition of
nducibility Using Multivariate Cox Models
Outcome:
Inducibility
Definition
Hazard
Ratio
95%
Confidence
Intervals p Value
T or VF
Narrow 1.56 1.10–2.21 0.012
Standard 1.34 0.95–1.90 0.094
Broad 1.27 0.90–1.79 0.16
T
Narrow 1.89 1.31–2.74 0.001
Standard 1.66 1.15–2.40 0.007
Broad 1.63 1.13–2.35 0.009
F
Narrow 0.41 0.14–1.17 0.096
Standard 0.41 0.16–1.09 0.073
Broad 0.40 0.16–0.99 0.049
eath
Narrow 0.68 0.39–1.18 0.17
Standard 0.58 0.34–0.99 0.045
Broad 0.59 0.36–0.97 0.039
T, VF, or death
Narrow 1.31 0.97–1.79 0.08
Standard 1.12 0.83–1.52 0.45
Broad 1.03 0.77–1.39 0.85
linical variables entering the models along with inducibility included heart rate 80
eats/min, NYHA functional class II, absence of treatment with beta-blockers, and
UN 25. Results for VT or VF, VT and VF are not fully reliable due to the
ecessity of having to censor patients without events upon death.
BUN  blood urea nitrogen; NYHA  New York Heart Association; VF 
entricular fibrillation; VT  ventricular tachycardia.
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EPS in the MADIT II Study January 3, 2006:98–107or VF (HR 0.41; p  0.073) after adjusting for the same
linical variables.
CD therapy events related to alternative definitions of
nducibility. The narrow definition of inducibility (mono-
orphic VT only) predicted the occurrence of the compos-
te event, VT or VF, better than the standard definition (p
0.038), as illustrated by comparing Figure 2A with Figure
A. This was mainly a result of the strong association
igure 2. Cumulative probability of first appropriate therapy for (A)
entricular tachycardia (VT) or ventricular fibrillation (VF); (B) VT only;
nd (C) VF only in patients with and without inducible arrhythmias
ccording to narrow definition of inducibility. Determination of p values
as from the log rank test.etween narrow inducibility and VT (p  0.002) (Fig. 2B). narrow inducibility was not significantly associated with the
ccurrence of VF only (Fig 2C), but a trend was neverthe-
ess still present for inducible patients to have less VF.
On the other hand, analogous graphs, such as Figures 1
nd 2, that use the broad definition (not shown) were
imilar to the standard definition, but with slightly less
eparation in the inducible and noninducible curves both for
T only or for VT and VF events. The broad definition
ppeared to perform inferiorly to the standard definition for
redicting VT or VF (p  0.45) or for predicting VT only
p  0.06) using log-rank analysis. For predicting the
ccurrence of VF therapy, broad inducibility, like the other
wo definitions, was associated with a lower risk of VF (p 
.04), which in this case was statistically significant.
Table 2 also shows results of multivariate Cox analyses
esting the association between alternative definitions of EP
nducibility and outcome. Therapy for VT or VF was
ignificantly predicted by inducibility per the narrow defi-
ition (HR 1.56; p 0.012), which was mainly the result of
etter performance of narrow inducibility for predicting
CD therapy for VT (HR 1.89; p  0.001).
The relationship between the broad definition of induc-
bility and outcome (Table 2) did not show a significant
ssociation for the composite end point of VT plus VF.
road inducibility was associated with VT (HR 1.63; p 
.009) but not as strongly as narrow or even standard
nducibility. Broad inducibility was associated with a lower
isk of VF (HR 0.40; p  0.049).
Analogous to refining the definition of inducibility, we
xamined whether the cycle length of the induced VT
mpacts on the subsequent likelihood for the occurrence of
T. Previous studies in the early post-MI period (15–17)
ave suggested that inducible monomorphic VT with a very
hort cycle length may be less likely to predict subsequent
T. We subdivided the arrhythmias categorized as induc-
ble by cycle length of the induced arrhythmia. Figure 3
emonstrates that the induction of extremely rapid VT
igure 3. Cumulative probability of first therapy for ventricular tachycardia
VT) in relationship to cycle length of induced VT. The cycle length of
nduced VT is divided at median value of 240 ms. The induction of a
lower VT (240 ms) was more predictive of the subsequent clinical
ccurrence of VT than the induction of rapid VT (240 ms), or
oninducibility (solid line).
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January 3, 2006:98–107 EPS in the MADIT II Study240 ms) did not predict the subsequent occurrence of VT
etter than noninducibility, whereas induction of VT with a
L240 ms led to a higher chance of subsequent VT (p
.001).
CD therapy events related to mortality and combined
nd point of VT/VF/death. Inducible patients (by the
tandard definition) had a lower mortality than noninduc-
ble individuals (p  0.012), as shown in Figure 4A. Using
ultivariate analysis (Table 2), we also found inducibility to
e independently, although weakly, associated with im-
roved survival (HR 0.58; p  0.045). Because inducibility
orrelated positively with VT events but inversely with both
F and mortality, inducibility did not predict the composite
nd point of VT, VF, or death by either univariate (Fig. 4B)
r multivariate analysis (Table 2). Using the narrow induc-
bility definition, we discovered that mortality in the induc-
ble group was not significantly lower by multivariate
nalysis (Table 2).
Because ICD interrogations were infrequently available
ostmortem, we compiled another composite end point con-
isting of ICD therapy for VT, ICD therapy for VF, or sudden
eath (without previous appropriate ICD therapy) to ensure
hat a fatal first arrhythmic event was not excluded. How-
ver, using deaths classified as sudden is well known to
igure 4. The cumulative probability of (A) mortality and (B) combined
nd point of ventricular tachycardia or ventricular fibrillation or death in
atients with and without inducible tachyarrhythmias according to stan-
ard definition of inducibility.verestimate true arrhythmic events because of the potential
l
(or other vascular events (e.g., cerebral hemorrhage, aortic
neurysm, pulmonary embolism) to present suddenly. Fig-
re 5 shows the event rates for this composite end point for
nducible and noninducible patients, using the standard as
ell as the narrow definition. As shown, this analysis is not
ppreciably different from that for the composite end point
f VT or VF (shown in Figs. 1A and 2A) because total
udden deaths in patients with ICDs were low and similar
n noninducible and inducible patients (5.7% and 4.3% at
our years for noninducible and inducible subsets, respec-
ively).
CD therapy events related to the combination of QRS
uration and EP inducibility. Figure 6A shows the ICD
vent rates for the combined end point of VT/VF for
atients with a narrow QRS (0.12 s) by inducibility status
ccording to the standard definition. Figure 6B shows the
CD event rates for patients with a wide QRS (0.12 s).
nducibility was predictive for VT/VF only in the patients
ith prolonged baseline QRS duration. Unfortunately, the
ombination of QRS duration and inducibility status failed
o identify a subgroup of patients at low arrhythmic risk in
hom ICD implantation could be deferred (Figs. 6A and
B). Because the analysis of QRS duration and inducibility
as not prespecified, we did not subject this data to
igure 5. The cumulative probability of the composite end point of
ppropriate implantable cardioverter-defibrillator (ICD) therapy for ven-
ricular tachycardia (VT), appropriate ICD therapy for ventricular fibril-
ation (VF), or sudden death for inducible versus noinducible patients using
A) the standard definition and (B) the narrow definition.
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EPS in the MADIT II Study January 3, 2006:98–107roportional hazards analysis. The conclusions above apply
hether we use the standard definition of inducibility (Figs.
A and 6B) or the narrow definition (data not shown).
ISCUSSION
n summary, EP inducibility in post-MI patients with
jection fraction of 0.30 or less did correlate with the
ubsequent occurrence of VT. However, inducibility had an
nverse relationship with VF requiring ICD therapy. The
nverse relationship with VF decreased the association
etween EP inducibility and the combined end point of VT
r VF. Because both inducible and noninducible patients
eceived ICD therapy, this MADIT II substudy is unique in
eing able to compare arrhythmic events broken down into
ither VT or VF in patients with differing inducibility
tatus.
Previous studies have found that EP inducibility is best
efined by the induction of sustained monomorphic VT, as
pposed to VF (4,18–20). Thus, our finding that VT
nducibility predicts the occurrence of VT but not VF is not
ntirely unexpected. In fact, restricting the definition of
nducibility to only include induction of monomorphic VT
igure 6. Cumulative probability of first appropriate therapy for either
entricular tachycardia (VT) or ventricular fibrillation (VF) in patients with
nd without inducible arrhythmias according to standard definition of
nducibility in (A) patients with QRS 0.12 s and (B) patients with QRS
0.12 s. Determination of p values was from the log rank test.the narrow definition) improves the correlation of induc- pbility with the subsequent occurrence of VT (Fig. 2B vs.
ig. 1B). Conversely, the broad definition was least strongly
ssociated with subsequent VT episodes. It appears, there-
ore, that future studies seeking to predict VT events should
se this “narrow” definition of inducibility. Moreover, in-
uction of ventricular arrhythmia with a cycle length 240
s was associated with a higher incidence of VT events in
ollow-up (Fig. 3) than induction of ventricular arrhythmia
ith a cycle length shorter than 240 ms. Although induc-
bility correlates with subsequent VT, only 39% of inducible
atients were estimated to experience a clinical VT episode
y three years, compared with 25% of noninducible patients.
Inducible MADIT II study patients tended toward a
ower likelihood of experiencing a spontaneous clinical
entricular fibrillation episode requiring ICD intervention
Figs. 1C and 2C). However, using multivariate analysis, we
iscovered that inducibility was not significantly associated
ith a reduced incidence of VF except by the broad
efinition (Table 2). At three years, 9% of noninducible
atients required treatment for at least one episode of clinical
entricular fibrillation by their defibrillator compared with 5%
f inducible patients, using the standard inducibility defini-
ion. Although this inverse relationship or trend is seem-
ngly paradoxical, EP inducibility relates best to the stable,
eentrant arrhythmia monomorphic VT and less well to VF.
entricular fibrillation, especially in the setting of advanced
ongestive heart failure, may rely on focal or triggered
echanisms in addition to re-entry (21–24). Ischemia is
ery likely to be implicated in spontaneous VF episodes in
atients with coronary artery disease (25).
Indeed, a recent paper from the MADIT II study
atabase found that patients who experienced VF in
ollow-up were more likely than VT patients or patients
ithout ICD therapy to be hospitalized for congestive heart
ailure (26). Such arrhythmias brought on by advanced
ongestive heart failure are perhaps more likely in patients
aving an ejection fraction 0.30. Thus, the presence of
dvanced congestive heart failure predicted VF as opposed
o VT in multivariate analysis whereas inducibility was
nversely related to subsequent VF. Electrophysiologic in-
ucibility evaluates the substrate for a reentrant arrhythmia,
hich is one contributor to the risk for sudden death, along
ith triggering factors, such as premature beats, autonomic
one and other factors. This inverse relation between induc-
bility and occurrence of clinical ventricular fibrillation in a
ay is not paradoxical when seen in this context. Thus,
atients who have a triggering event and go on to have a
linical ventricular arrhythmia are more likely to have VT as
heir arrhythmia if they are found to have a substrate for VT
t EP study, whereas those without such a demonstrated
ubstrate would be more likely to have clinical VF if a
riggering event initiated an arrhythmia.
Recent work has ascribed VF to a two-part process
nvolving VT (spiral wave) initiation, and then spiral wave
isorganization dependent upon the slope of the action
otential duration-diastolic interval relationship, also called
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January 3, 2006:98–107 EPS in the MADIT II Studyhe restitution slope (24,27,28), although this concept is
ontroversial (29–32). One could speculate that if stable
onomorphic VT were induced in the EP laboratory, and
id not degenerate to VF in that setting, that a spontaneous
entricular arrhythmia might be less likely to (rapidly)
egenerate into VF. Patients who maintain a stable rotor or
eentry circuit in the EP laboratory could conceivably have
different restitution slope than those who do not exhibit
nducible monomorphic VT. Inducibility of a monomorphic
T might identify a patient whose arrhythmia is less likely
o deteriorate into VF (at least early after onset).
Although these data demonstrate shortcomings of EP
nducibility, recent data from the MUSTT study are in
act quite concordant (5). In the MUSTT study (5), the
wo-year total mortality in patients with an ejection
raction 0.30 was 33% in inducible patients and 26% in
oninducible patients, yielding an unadjusted risk ratio of
.27, which is very similar to the HR of 1.34 for the
ombined VT and VF end point we found (Table 2).
sing the MUSTT study data on arrhythmic death or
ardiac arrest also yields a similar unadjusted risk ratio of
.4 for inducibility in the low ejection fraction subgroup
5). In the MUSTT study, EP inducibility was less
redictive of mortality or arrhythmic death in the lower
jection fraction strata, the MADIT II-like subset of the
USTT study, than in the patients whose ejection
raction was between 0.30 and 0.40. Unlike the MADIT
I study, the relative contribution of VT as opposed to
F to sudden death mortality could not be differentiated
n the MUSTT study because noninducible patients and
ontreatment arm patients did not receive an ICD.
nlike the data in this MADIT II substudy or those from
he MUSTT study, many earlier publications supporting the
ole of EP testing suffer one or more limitations, including the
se of sudden death as opposed to total mortality as an end
oint, inhomogeneous populations with varying severity of
tructural heart disease, and differing treatments for induc-
ble and noninducible patients at a time before recognition
f the proarrhythmic effects of pharmacologic agents
11,15–18,33).
In the MADIT II study, inducibility did not correlate
ith increased mortality; in fact inducible patients tended
o have a lower mortality rate (Fig. 4A), although this
nding was of only borderline significance using multi-
ariate analysis (Table 2). The (slightly) reduced, as
pposed to increased mortality associated with inducibil-
ty in this study, is not paradoxical because both inducible
nd noninducible MADIT II study groups were treated
ith an ICD as opposed to the MUSTT study. Electro-
hysiologic testing did predict a greater occurrence of
T, but VT is virtually always successfully treated by the
CD and, thus, inducibility was not associated with
ncreased mortality. Likewise, in the AVID study induc-
bility did not predict an inferior survival (34).
The imperfect predictability of EP testing shown inhis study is not attributable to differences with previously hsed EP protocols. The Electrophysiologic Study Versus
lectrocardiographic Monitoring (ESVEM) trial, which
ound EP inducibility poorly predictive, was criticized for
he EP protocol being insufficiently aggressive. In the
ADIT II study, however, a rigorous induction protocol
onsisting of triple extrastimuli at two RV sites and two
ycle lengths was used. Attesting to the aggressive nature
f the protocol, the MADIT II study investigators found
relatively high inducibility rate of 36% (211 of 593),
imilar to the 35% inducibility reported in the MUSTT
tudy. Nevertheless, noninducible patients had 64% as
reat a chance of experiencing VT by three years as did
nducible patients (Fig. 1B), suggesting that this well-
alidated protocol is relatively insensitive in patients with
n ejection fraction 0.30.
tudy limitations. This report has several possible limi-
ations, one of which is the lack of availability of ICD
rogramming details, which was left to investigator
reference in the MADIT II study. Theoretically, this
ould affect the degree of detection of VT. For instance,
f a slow VT were induced at EP study, this could have
ncouraged the investigator to program a slow detection
ate, which could increase the yield of VT events in
ollow-up. This could conceivably increase the correla-
ion between VT inducibility and VT events. It appears
hat this would have been a very infrequent occurrence,
ecause only five patients had inducible VT at a rate
170 beats/min. On the other hand, alterations in
rogramming would be very unlikely to have affected the
etection of VF events, leading to the inverse relation
etween inducibility and VF events. Varying the lower
one detection rate would not effect detection of VF. The
etection time for VF is not programmable for the ICD
evices used in this study. A self-terminating arrhythmia
hat did not lead to ICD therapy was not classified as
ither VT or VF in this study.
A second potential limitation is that not all patients
nderwent an EP study. As noted previously, the clinical
haracteristics of patients having an EP study versus
hose not having an EP study did not differ in clinically
elevant characteristics. Moreover, patients undergoing
n EP study had similar event rates for VT or VF, CHF
ospitalization or death, in follow-up to those patients
ot undergoing an EP study. Third, the findings concerning
he predictive value of the EP test for VT or VF are specific to
he EP testing protocol used. Protocols using more than three
xtrastimuli, which may induce VT in a greater proportion of
atients (35–37) or other variations could possibly have led to
ifferent findings. As noted previously, theMUSTT study, the
argest other study prospectively after patients with remoteMI,
sed a virtually identical protocol to the MADIT II study
rotocol. In addition, we found that the induction of VT
ended to be inversely related to the occurrence of VF in
ollow-up, no matter which inducibility definition was used.
ourth, concerning the tendency of noninducible patients to
ave an increased likelihood of VF, the classification of
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EPS in the MADIT II Study January 3, 2006:98–107vents as VT or as VF relies on arbitrary definitions and
oes involve potentially subjective electrogram data inter-
retation. Thus, one should not overinterpret the tendency
oward more VF in the noninducible group, a trend that was
ot statistically significant by multivariate analysis. Finally,
hese data pertain to the relationship between inducibility
nd subsequent VT or VF episodes. The occurrence of VT
r VF treatment by an ICD should not be equated with a
ortal event because some episodes undoubtedly would
ave terminated spontaneously if the ICD had not inter-
ened. The magnitude of this effect is observed when
omparing the incidence of a first ICD therapy for VT or
F, 27% at two years (26), with the difference in total
ortality between ICD and conventional groups, 6% at two
ears (38).
onclusions. We found a limited predictive value of EP
esting using a stimulation protocol using up to three
xtrastimuli at two sites for ruling out subsequent VT or VF
vents. Although noninducible patients in the MADIT II
tudy population do have a slightly lower risk of the combined
rrhythmic end point of VT or VF, their risk of VF tended to
e higher than in inducible patients. Thus, for postinfarction
atients with an ejection fraction of 0.30, noninducibility
t EP testing does not equate with a low arrhythmic risk.
his study does not support excluding noninducible patients
rom ICD therapy.
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